KR100899491B1 - 티아졸릴 아미드의 국소 용도 - Google Patents

티아졸릴 아미드의 국소 용도 Download PDF

Info

Publication number
KR100899491B1
KR100899491B1 KR1020037016645A KR20037016645A KR100899491B1 KR 100899491 B1 KR100899491 B1 KR 100899491B1 KR 1020037016645 A KR1020037016645 A KR 1020037016645A KR 20037016645 A KR20037016645 A KR 20037016645A KR 100899491 B1 KR100899491 B1 KR 100899491B1
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
mono
halo
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037016645A
Other languages
English (en)
Korean (ko)
Other versions
KR20040030689A (ko
Inventor
울리크 베츠
토비아스 라이크
볼프강 벤더
뤼디거 피슈어
마르틴 헨드리크스
제랄트 클라이만
Original Assignee
아이쿠리스 게엠베하 운트 코. 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쿠리스 게엠베하 운트 코. 카게 filed Critical 아이쿠리스 게엠베하 운트 코. 카게
Publication of KR20040030689A publication Critical patent/KR20040030689A/ko
Application granted granted Critical
Publication of KR100899491B1 publication Critical patent/KR100899491B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
KR1020037016645A 2001-06-22 2002-06-10 티아졸릴 아미드의 국소 용도 Expired - Fee Related KR100899491B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10129714A DE10129714A1 (de) 2001-06-22 2001-06-22 Topische Anwendung von Thiazolylamiden
DE10129714.9 2001-06-22
PCT/EP2002/006327 WO2003000259A1 (de) 2001-06-22 2002-06-10 Topische anwendung von thiazolylamiden

Publications (2)

Publication Number Publication Date
KR20040030689A KR20040030689A (ko) 2004-04-09
KR100899491B1 true KR100899491B1 (ko) 2009-05-26

Family

ID=7688817

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037016645A Expired - Fee Related KR100899491B1 (ko) 2001-06-22 2002-06-10 티아졸릴 아미드의 국소 용도

Country Status (17)

Country Link
US (1) US7883713B2 (https=)
EP (2) EP1629842B1 (https=)
JP (1) JP4342304B2 (https=)
KR (1) KR100899491B1 (https=)
CN (1) CN1535149B (https=)
AT (2) ATE320253T1 (https=)
AU (1) AU2002345023B2 (https=)
BR (1) BRPI0210601B8 (https=)
CA (1) CA2451552C (https=)
DE (3) DE10129714A1 (https=)
DK (2) DK1629842T3 (https=)
ES (2) ES2341778T3 (https=)
IL (1) IL159258A0 (https=)
MX (1) MXPA03011518A (https=)
PL (1) PL208927B1 (https=)
PT (2) PT1401435E (https=)
WO (1) WO2003000259A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129715A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
JP6918823B2 (ja) 2016-04-06 2021-08-11 イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ 抗ウイルス剤として有用なアミノチアゾール誘導体
LT3544976T (lt) 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
AR110251A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
AR110250A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323045A (en) 1970-01-16 1973-07-11 Shell Int Research 2-acylaminothiazole derivatives and their use as herbicides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658830A (en) * 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3717651A (en) * 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
GB2080682B (en) * 1980-07-30 1984-03-28 Ciba Geigy Ag Antiherpetically active lipstick
US4556560A (en) * 1983-01-24 1985-12-03 The Procter & Gamble Company Methods for the treatment and prophylaxis of diaper rash and diaper dermatitis
DE3319282A1 (de) * 1983-05-27 1984-11-29 Gödecke AG, 1000 Berlin Verwendung von adenosin bei der behandlung von herpes
ES2186811T3 (es) 1995-12-29 2003-05-16 Boehringer Ingelheim Pharma Derivados de feniltiazol con propiedades anti-virus herpes.
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
NZ507032A (en) 1998-03-19 2003-06-30 Pharmacia & Upjohn 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections
WO2000053591A1 (de) * 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
EP1319185A1 (en) * 2000-06-15 2003-06-18 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323045A (en) 1970-01-16 1973-07-11 Shell Int Research 2-acylaminothiazole derivatives and their use as herbicides

Also Published As

Publication number Publication date
AU2002345023B2 (en) 2007-07-12
EP1401435B1 (de) 2006-03-15
BR0210601A (pt) 2004-09-28
IL159258A0 (en) 2004-06-01
PL364378A1 (en) 2004-12-13
JP2004534818A (ja) 2004-11-18
CN1535149A (zh) 2004-10-06
BRPI0210601B1 (pt) 2016-08-23
WO2003000259A1 (de) 2003-01-03
US7883713B2 (en) 2011-02-08
ATE464047T1 (de) 2010-04-15
EP1401435A1 (de) 2004-03-31
EP1629842A1 (de) 2006-03-01
DK1401435T3 (da) 2006-07-17
MXPA03011518A (es) 2004-10-28
CA2451552A1 (en) 2003-01-03
DE50214378D1 (de) 2010-05-27
PT1401435E (pt) 2006-07-31
CN1535149B (zh) 2012-06-06
KR20040030689A (ko) 2004-04-09
ES2341778T3 (es) 2010-06-28
CA2451552C (en) 2011-11-08
JP4342304B2 (ja) 2009-10-14
PT1629842E (pt) 2010-05-10
ES2260449T3 (es) 2006-11-01
PL208927B1 (pl) 2011-06-30
ATE320253T1 (de) 2006-04-15
BRPI0210601B8 (pt) 2021-05-25
DK1629842T3 (da) 2010-08-02
EP1629842B1 (de) 2010-04-14
HK1069986A1 (en) 2005-06-10
US20040235917A1 (en) 2004-11-25
DE50206084D1 (de) 2006-05-11
DE10129714A1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
JP4726175B2 (ja) チアゾリルアミド誘導体
KR100899491B1 (ko) 티아졸릴 아미드의 국소 용도
JP7165123B2 (ja) 医薬製剤
CN102627639A (zh) 丙型肝炎病毒的大环抑制剂
AU2022271435A1 (en) Ophthalmic compositions
JP2011510965A (ja) 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体
JPWO2017104725A1 (ja) 創傷治療剤
JP2023062143A (ja) 水性組成物
DE10129716A1 (de) Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) Kombinationspräparate zur Herpes-Behandlung
HK1069986B (en) Topical application of thiazolyl amides
US20130079290A1 (en) S1p antagonists as adjunct ocular hypotensives
JP2004534819A (ja) チアゾリルアミド類および抗ウイルス医薬としてのそれらの使用
ZA200309800B (en) Topical application of thiazolyl amides
DE10039265A1 (de) Thiazolylamid-Derivate
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20120514

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130510

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140508

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20150512

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20160509

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20170512

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220520

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220520